HeartBeam has been awarded a new US patent covering acoustic sensing and thoracic impedance measurement technologies for its credit card-sized, cable-free ECG device, expanding its potential use in monitoring structural heart disease and heart failure.

The patent protects the integration of acoustic sensors into the device's foldable arms, allowing it to function as a digital stethoscope. The sensors are designed to capture heart valve sounds, including those produced by the mitral and tricuspid valves, providing additional information on the heart's mechanical and structural function.

The patent also covers thoracic impedance measurement, which uses a small electrical current and voltage measurements to estimate fluid levels in the chest. This capability could help identify fluid build-up in patients with heart failure before symptoms become severe, enabling earlier clinical intervention and potentially reducing hospital admissions.

Unlike wrist- or finger-worn wearable devices, HeartBeam's portable ECG is used directly on the chest, allowing it to capture both heart sounds and thoracic impedance measurements from the most relevant anatomical location.

Heart failure affects approximately 6.7 million adults in the United States and is a major cause of hospitalisation. Earlier detection of fluid accumulation could improve patient outcomes while lowering healthcare costs by supporting timely treatment adjustments.

The newly granted patent increases HeartBeam's intellectual property portfolio to 26 issued patents worldwide, covering areas including signal acquisition, ECG algorithms, diagnostic applications and device hardware. The company said the patent supports its strategy of developing a multi-modal remote cardiac monitoring platform that combines ECG, heart sound analysis and fluid monitoring in a single patient-operated device.

 

Source: businesswire.com

Report Abuse